NO20074855L - Anvendelse av et modifisert poxvirus for den rapide induksjonen av immunitet mot et poxvirus eller andre smittsomme midler - Google Patents

Anvendelse av et modifisert poxvirus for den rapide induksjonen av immunitet mot et poxvirus eller andre smittsomme midler

Info

Publication number
NO20074855L
NO20074855L NO20074855A NO20074855A NO20074855L NO 20074855 L NO20074855 L NO 20074855L NO 20074855 A NO20074855 A NO 20074855A NO 20074855 A NO20074855 A NO 20074855A NO 20074855 L NO20074855 L NO 20074855L
Authority
NO
Norway
Prior art keywords
pox virus
rapid induction
animal
antigen
modified
Prior art date
Application number
NO20074855A
Other languages
English (en)
Other versions
NO347468B1 (no
Inventor
Paul Chaplin
Luis Mateo
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074855(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20074855L publication Critical patent/NO20074855L/no
Publication of NO347468B1 publication Critical patent/NO347468B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen angår hurtig induksjon av en beskyttende immunrespons mot poxvira og poxvirusinfeksjoner så som kopper ved vaksinasjon av et dyr, inkludert et menneske, med et poxvirus som er replikasjonsinkompetent i nevnte dyr, inkludert mennesket. Et eksempel på et slikt poxvirus er et modifisert Vacciniavirus Ankara (MVA). Oppfinnelsen angår videre bruken av et rekombinant poxvirus som er replikasjonsinkompetent i dyret, inkludert mennesket, som blir vaksinert med viruset så som et rekombinant MVA som uttrykker heterologe antigener og/eller antigenepitoper for hurtig induksjon av en beskyttende immunrespons mot nevnte heterologe antigen og/eller antigenepitop, for eksempel mot et antigen og/eller antigenepitop som er del av et infeksiøst middel.
NO20074855A 2005-02-23 2006-02-17 Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering. NO347468B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003873 2005-02-23
PCT/EP2006/001447 WO2006089690A1 (en) 2005-02-23 2006-02-17 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents

Publications (2)

Publication Number Publication Date
NO20074855L true NO20074855L (no) 2007-10-26
NO347468B1 NO347468B1 (no) 2023-11-13

Family

ID=34933889

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074855A NO347468B1 (no) 2005-02-23 2006-02-17 Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering.

Country Status (25)

Country Link
US (3) US20110142877A1 (no)
EP (1) EP1855720B2 (no)
JP (3) JP2008531489A (no)
KR (1) KR20070110007A (no)
CN (1) CN101128217B (no)
AU (1) AU2006218115B2 (no)
BR (1) BRPI0608310A2 (no)
CA (1) CA2593532C (no)
CY (1) CY1118573T1 (no)
DK (1) DK1855720T4 (no)
EA (1) EA013404B1 (no)
ES (1) ES2608627T5 (no)
FI (1) FI1855720T4 (no)
HU (1) HUE030037T2 (no)
IL (1) IL184347A (no)
LT (1) LT1855720T (no)
MX (1) MX2007010158A (no)
MY (1) MY162027A (no)
NO (1) NO347468B1 (no)
NZ (1) NZ556409A (no)
PT (1) PT1855720T (no)
SI (1) SI1855720T2 (no)
UA (1) UA100836C2 (no)
WO (1) WO2006089690A1 (no)
ZA (1) ZA200706078B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128217B (zh) † 2005-02-23 2012-04-25 巴法里安诺迪克有限公司 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
US8268327B2 (en) * 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EA034825B1 (ru) * 2013-03-15 2020-03-25 Бавариан Нордик А/С Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
FR3171450A1 (fr) 2025-01-17 2026-07-24 Odimma Therapeutics Virus enveloppé pour la transfection d’acides nucléiques exogènes.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82479C2 (uk) * 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
AU2003264144C1 (en) † 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
CA2511625A1 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
US6960345B2 (en) * 2003-03-06 2005-11-01 Incell Corporation, Llc Oral vaccinia formulation
WO2004087201A2 (en) * 2003-03-28 2004-10-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva virus expressing modified hiv envelope, gag, and pol genes
CN101128217B (zh) † 2005-02-23 2012-04-25 巴法里安诺迪克有限公司 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA

Also Published As

Publication number Publication date
EA200701801A1 (ru) 2008-02-28
ZA200706078B (en) 2012-10-31
SI1855720T2 (sl) 2023-07-31
MY162027A (en) 2017-05-31
PT1855720T (pt) 2016-12-14
ES2608627T3 (es) 2017-04-12
AU2006218115A1 (en) 2006-08-31
HK1113466A1 (en) 2008-10-03
ES2608627T5 (es) 2023-10-04
IL184347A0 (en) 2007-10-31
CA2593532A1 (en) 2006-08-31
UA100836C2 (ru) 2013-02-11
BRPI0608310A2 (pt) 2009-12-08
US8808709B2 (en) 2014-08-19
WO2006089690A9 (en) 2012-10-04
EP1855720A1 (en) 2007-11-21
US9265823B2 (en) 2016-02-23
WO2006089690A1 (en) 2006-08-31
DK1855720T3 (da) 2017-01-16
JP2008531489A (ja) 2008-08-14
EA013404B1 (ru) 2010-04-30
JP5952112B2 (ja) 2016-07-13
JP2012193198A (ja) 2012-10-11
CN101128217A (zh) 2008-02-20
CY1118573T1 (el) 2017-07-12
US20140341946A1 (en) 2014-11-20
KR20070110007A (ko) 2007-11-15
DK1855720T4 (da) 2023-07-24
FI1855720T4 (fi) 2023-08-31
CA2593532C (en) 2017-05-02
NO347468B1 (no) 2023-11-13
SI1855720T1 (sl) 2017-01-31
AU2006218115B2 (en) 2012-08-02
HUE030037T2 (en) 2017-04-28
JP2016104822A (ja) 2016-06-09
EP1855720B2 (en) 2023-04-26
CN101128217B (zh) 2012-04-25
IL184347A (en) 2016-07-31
NZ556409A (en) 2010-09-30
US20110142877A1 (en) 2011-06-16
LT1855720T (lt) 2017-01-10
US20120107359A1 (en) 2012-05-03
MX2007010158A (es) 2007-10-16
EP1855720B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
Gupta et al. TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice
CY1118573T1 (el) Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων
MX2022009989A (es) Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
PH12017500727A1 (en) Modified virus-like particles of cmv
CL2014002415A1 (es) Composición inmunogénica que permite aumentar una respuesta inmunitaria a un patógeno, particularmente viral, que comprende una glicoproteína antigénica del patógeno, donde la glicoproteina está parcialmente glicosilada en al menos un sitio de glicosilación; y vacuna útil para inmunizar un mamífero (div. sol. n° 2354-11).
EA201892735A1 (ru) Состав вакцины против hiv
EA201171128A1 (ru) Оптимизированный ранний/поздний промотор в сочетании с повторной вакцинацией способствует ответу цитотоксических т- клеток против антигенов рекомбинантных вакцин, основанных на вирусе с дефицитом по репликации
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
Hoxie et al. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
WO2016130560A3 (en) Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
PH12016502389A1 (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
MX2022007398A (es) Vacunas contra el virus de la fiebre porcina africana y métodos para usarlas.
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
BRPI0800485B8 (pt) vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
JP2016514114A5 (no)
WO2024031045A9 (en) Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
ZA202213407B (en) Compositions and methods of manufacturing trivalent filovirus vaccines
Quinan et al. Modified vaccinia virus Ankara as vaccine vectors in human and veterinary medicine
WO2024233996A3 (en) Vaccines against african swine fever virus, and methods of using same
de Leeuw et al. Rift Valley Fever Vaccine Development, Progress and Constraints